Octave Biotech Consulting is a business development and strategy consulting firm to the life sciences industry. Based in Geneva, Switzerland since 2012, our clients include small and large biotech and pharmaceutical firms, non-profit foundations, academic institutions, and investors.

Our skills and experience are at your service to help you to grow your company and find the best partner for your assets.

About Sylvie

I am a business development executive with over twenty years of experience covering all aspects of pharmaceutical business development and alliance management.  My clients are life sciences companies in Europe and the US. I am also a Board Member of Domain Therapeutics and the International Brain Research Organization (IBRO), and an Adjunct Professor at the Grenoble School of Management where I teach an advanced Masters course on Business Development.

Prior to establishing my consulting practice, I spent twelve years within Index Ventures, Serono International, and Merck KGaA where, as Global Head of Licensing in neurology, dermatology, and autoimmune diseases, I managed a team of business development professionals and was instrumental in numerous product and technology transactions as well as several startup creations.

I earned a PhD in Neurobiology at the California Institute of Technology before completing a postdoctoral fellowship at the Harvard Business School.  I went on to spend four years with strategic consultancy McKinsey & Company before joining the pharmaceutical industry. 

Sylvie Ryckebusch
Founder, Octave Biotech Consulting 

Services

How can I help you

Develop a business
development strategy

Perform competitive analysis

Manage due diligence process for
in-licensing or out-licensing projects

Attend partnering conferences

Identify potential partners and manage discussions

Build full risk-adjusted net present value financial models for your assets

Negotiate term sheets
and license agreements

Review agreements and
advise on contractual questions

Restructure and
amend license agreements

Values

I apply the highest ethical and professional standards to the work I do every day, while keeping my costs low so my biotech clients can focus on their core business: developing new medecines.

Selected Transactions

Product License Agreements
  • BioInvent and Cancer Research UK (BI-1206)-2021
  • BioInvent and CASI Pharmaceuticals (BI-1206)-2020
  • EspeRare and Pierre Fabre (ER 004)-2020
  • Dermadis and QID Pharma (DM107)-2019
  • EspeRare and Edimer (ER004)-2018
  • EspeRare and Merck (Rimeporide)-2013
  • Merck and Ambrx (ARX-201)-2007
  • Serono and ZymoGenetics (FGF18, anti-IL22RA MAb, anti-IL31 Mab)-2004
  • Serono and ZymoGenetics (TACI-Ig)-2001
Medical Devices
  • Carthera and Lantheus Medical Imaging-2019
  • EBA-Med and Mayo Clinic-2019
  • Aleva and Dixi Medical-2019
  • Aleva and Greatbatch-2016
  • OTR3 and Chemineau-2016
  • OTR3 and Liaoning KRS Medical Technology-2016
  • Merck and Ventana-2013
  • Merck and Novo Nordisk-2012
Academic Technology Transfer
  • BioInvent and University of Southampton
  • HPlus and University of Geneva
  • Index Ventures and MIT
  • ND Biosciences and EPFL
  • AIDD and University of Geneva
  • Calypso and University of Bordeaux
  • EspeRare Foundation and University of Erlangen
  • Dermabiotech and University of Zurich
  • Immuthes and University of Geneva
  • Kylys and University of Geneva
  • MPC Therapeutics and University of Geneva
  • TwentyGreen and EPFL
  • Dermadis and INSERM
  • Dermadis and University of Lausanne
  • EspeRare Foundation and University of Bristol
Research Collaborations
  • DeepCDR and Twist-2018
  • Merck and Bionomics-2014
  • Merck and Biopharm-2013
  • Merck and Weizmann Institute-2012
  • Serono and Novo Nordisk and ZymoGenetics-2006
  • Serono and Dyax-2006
  • Serono and Paratek Pharmaceuticals-2004
  • Serono and Nautilus-2004
  • Serono and ZymoGenetics 2004
  • Serono and CGI Pharmaceuticals-2003
  • Serono and Regeneron Pharmaceuticals-2002
  • Serono and Inpharmatica-2001
  • Serono and Evotec-2001

Selected Clients

Contact

Mailing Address:

Octave Biotech Consulting
EPFL Innovation Park
15 avenue de Sécheron
1202 Genève
Switzerland

Telephone:
M: +41 (0)79 217 2694
Email:
Cette adresse e-mail est protégée contre les robots spammeurs. Vous devez activer le JavaScript pour la visualiser.

Thank you for your message. Please note we will only use your information to respond and not for any other purpose
Something failed, please try again.